S&T in Singapore

TUESDAY 29 NOVEMBER 2005
"Latest developments in S&T in Singapore with speakers from the British High Commission and BioSingapore"

Location: Asia House, 63 New Cavendish Street, London W1G 7LP
Nearest Tube Stations: Regents Park, Oxford Circus, Bond Street
Time: 5.30 - 7.30 pm
To Register: please click here

Chair Ed Bell, Managing Director, Crown Bio Systems

Speakers Dr Brian Ferrar, First Secretary, Science & Technology, British High Commission, Singapore
Dr Steven Fang, Head BioSingapore & Chief Executive of Cygenics

Background

Brian Ferrar, First Secretary, Science & Technology, British High Commission Singapore

Brian spent most of his early career in the UK Department of Energy. He joined DTI in 1992 and was part of the team responsible for the privatisation of AEA Technology plc. From 1996 to 1999 he was Assistant Director of the Foresight Programme in the OST responsible for Health and Life Sciences, Materials, Chemicals and Manufacturing. He then became Head of the DTI's International Technology Service where he was Chairman of the UK-Russia High Technology Working Group and responsible for the establishment of the UK-Israel BRITECH Foundation.

In 2000 Brian joined the British Embassy in Tokyo as First Secretary S&T where, among other things, he was responsible creating the Innovation UK campaign. He moved to his current position as First Secretary S&T in Singapore in January 2004. Since his arrival in Singapore he has run the UK-Singapore Partners in Science campaign. The success of the campaign was recognised by the Prime Ministers of the UK and Singapore who in July 2005 decided to convert it into a long term UK-Singapore initiative to promote collaboration and help build scientific capacity in SE Asian countries.

Steve Fang, Head BioSingapore & Chief Executive of Cygenics

Steven Fang is Group CEO of CyGenics, a cell therapy company focused on the development and commercialisation of adult stem cell-related products, services, applications and technologies. From its headquarters in Australia, CyGenics operates four subsidiaries: Singapore-based CordLife (tissue banking services, in particular, cord blood banking) and Cell Sciences (consumable cell culture products), and Cytomatrix (cell therapeutics and technology development) based in Boston, USA, and CytoVations (new product development) based in New Jersey, USA. CyGenics is listed on the Australian Stock Exchange, under the symbol CYN. For more information, please visit www.cygenics.com.

In addition to holding an office with BioSingapore as Chairman, Mr Fang is currently also the President of Spirit of Entreprise (a non-profit organisation to recognise and promote entrepreneurship), Board Member of ACE /IAC of IE Singapore for Globalisation and Board member of the Singapore British Business Council.

Mr Fang is intimately familiar with the healthcare provider business, with over 15 years of sales and business development experience in the Asia Pacific region. He has previously worked for Sterling Withthrop, Baxter and Becton Dickinson, having undertaken business development assignments in Malaysia , Korea, Taiwan, and the Philippines, including the set up of private dialysis centres. While at Becton Dickinson, he was the General Manager for Singapore, Malaysia and Vietnam. More recently, Steven was the Director for Quality Healthcare Asia Ltd. Steven has a first degree in Computer Engineering, and completed his MBA with the University of Hull (UK) in business strategy.